Wednesday, July 8, 2026

pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA

Vanda Pharmaceuticals Netherlands

Vanda Pharmaceuticals Netherlands is a pharma organization headquartered in Washington, USA. It trades on NYSE under ticker VNDA. Primary therapeutic focus areas include Generalized Pustular Psoriasis, Schizophrenia, Maj

2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
Status
Public
HQ
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
Founded
2003
Employees
600
Programs
60
Drugs
19
Patents
96
Clinical program

Iloperidone

Phase 3 · small molecule · Bipolar I Disorder

Iloperidone for Bipolar I Disorder is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals Netherlands B.V. with 2 ClinicalTrials.gov record(s).

Internal code VP-VYV-683-1004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Vanda Pharmaceuticals Netherlands B.V.
Phase
Phase 3
Modality
small_molecule
Indication
Bipolar I Disorder
Status
completed
Trials
2